Page 30«..1020..29303132..4050..»

Battling Cancer with Nanotechnology – Video

§ June 16th, 2013 § Filed under Nano Medicine Comments Off on Battling Cancer with Nanotechnology – Video


Battling Cancer with Nanotechnology
"Battling Cancer with Nanotechnology" is a 6-minute video that shares the research of Mauro Ferrari, a leading pioneer in the field of cancer nanomedicine. A...

By: NISENet

Originally posted here:
Battling Cancer with Nanotechnology - Video

Read the Rest...

Battling Cancer with Nanotechnology (Spanish) – Video

§ June 15th, 2013 § Filed under Nano Medicine Comments Off on Battling Cancer with Nanotechnology (Spanish) – Video


Battling Cancer with Nanotechnology (Spanish)
"Battling Cancer with Nanotechnology" is a 6-minute video that shares the research of Mauro Ferrari, a leading pioneer in the field of cancer nanomedicine. A visionary optimist, Ferrari applied...

By: NISENet

Read the original:
Battling Cancer with Nanotechnology (Spanish) - Video

Read the Rest...

The vision of nanomedicine in Israel – Video

§ June 11th, 2013 § Filed under Nano Medicine Comments Off on The vision of nanomedicine in Israel – Video


The vision of nanomedicine in Israel
Lecturer: Dr. Silvia Noiman "Medical Nanosystems New Solutions to Stubborn Challenges", Tel Aviv University Board of Governors 2013, 6.6.13.

By: TAUVOD

Follow this link:
The vision of nanomedicine in Israel - Video

Read the Rest...

Cellular Surgeons: The New Era of Nanomedicine – Video

§ June 3rd, 2013 § Filed under Nano Medicine Comments Off on Cellular Surgeons: The New Era of Nanomedicine – Video


Cellular Surgeons: The New Era of Nanomedicine
The presentation is recorded at World Science Festival 2013 at The Kaye Playhouse at Hunter College. http://worldsciencefestival.com/events/cellular_surgeons?/events/kavli_nanoscience Robert...

By: Dennis O.

Original post:
Cellular Surgeons: The New Era of Nanomedicine - Video

Read the Rest...

Welcome to the Era of Nanomedicine – Video

§ June 2nd, 2013 § Filed under Nano Medicine Comments Off on Welcome to the Era of Nanomedicine – Video


Welcome to the Era of Nanomedicine
What if you could swallow a pill that conducts surgery? What can the world's tiniest robots do to DNA and cells? Harvard Medical School's Dr. Omid Farokhzad, one of the leading researchers...

By: WSJDigitalNetwork

See the original post:
Welcome to the Era of Nanomedicine - Video

Read the Rest...

Research and Markets: Nanotechnology Market Outlook 2017

§ May 25th, 2013 § Filed under Nano Medicine Comments Off on Research and Markets: Nanotechnology Market Outlook 2017

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/c3dk23/nanotechnology) has announced the addition of the "Nanotechnology Market Outlook 2017" report to their offering.

Nanotechnology has been the greatest impetus to technological and industrial development in the 21st century and has been recognized as the resource for the next industrial revolution. The evolving technology has already influenced a large number of industrial segments, and the economic activity generated from it has been high in magnitude and wide in scope. The nanotechnology-based products, which have had a huge impact on almost each industrial sector, are now entering the consumer market in a big way.

In their latest research study, Nanotechnology Market Outlook 2017, RNCOS' analysts have identified that the global nanotechnology industry has been growing at a rapid pace with rising applications in sectors like electronic, enegy, healthcare sector etc. In addition, market trends like nanotechnology-based thin film solar cells with high effieciency; nanomaterials with higher strength; robust growth in nanofibres and nanomedicine market; etc., are booming growth in this industry. Considering the above factors, the global nanotechnology market is anticipated to grow at a CAGR of around 19% during 2013-2017.

In the report, the analysts have studied the nanotechnology market by application, by component and by region. On the application front, they have analyzed nanotechnology use in electronics, energy, cosmetics, medical and defence sector. In addition, they have covered the current nanotechnology market and forecast for each of the above mentioned segments till 2017. In terms of component, the nanotechnology market can be segregated into nanomaterials, nanotools and nanodevices. The report covers their present and future shares in the market.

Further, country level analysis discusses nanotechnology market in major countries like USA, Germany, France, the U.K., Russia, etc., the present key growth drivers, and future directions for each nation. In addition, it covers the nanotechnology patent analyses, including number of patent publications and global top assignees of nanotechnology patent literature.

Besides this, the report covers the global R&D funding for the nanotechnology industry, including break-ups for corporate, public and venture capital funding along with their forecasts. The report even covers country-level analysis of R&D funding to provide in-depth understanding about investment related to nanotechnology.

With a view to providing a balanced outlook of the global nanotechnology market to clients, the report also includes the profiles of key industry players like Altair, Nanophase Tech and Nanosys, among others. Overall, the objective of the study is to help clients understand the prospects of the industry, and make sound investment decisions in view of the same.

Companies Mentioned

- Altair Nanotechnologies Inc.

Original post:
Research and Markets: Nanotechnology Market Outlook 2017

Read the Rest...

World Nanotechnology Market Potential Explored by RNCOS in New Topical Study Now Available at MarketPublishers.com

§ May 25th, 2013 § Filed under Nano Medicine Comments Off on World Nanotechnology Market Potential Explored by RNCOS in New Topical Study Now Available at MarketPublishers.com

LONDON--(BUSINESS WIRE)--

The global nanotechnology industry has been advancing at a robust rate in the recent past and it is likely to register a healthy CAGR of around 19% during 2013-2017. Major factors booming this growth include the growing penetration of nanotechnology into various industrial sectors; market trends such as the emergence of nanomaterials with higher strength, nanotechnology-based thin film solar cells with high efficiency, rapid popularity of nanofibres and nanomedicine, among others.

New market research study Nanotechnology Market Outlook 2017 elaborated by RNCOS E-Services Private Limited (RNCOS) is designed to give a refined understanding of the prospects of the global nanotechnology industry.

The research provides an in-depth review and forecast up to 2017 of the global nanotechnology market, segmented by application (electronics, energy, cosmetics, biomedical and defense), component (nanomaterials, nanotools and nanodevices) and by individual country the US, Brazil, Germany, France, the UK, Ireland, Russia, Japan, South Korea, Taiwan, China, India and Australia. The report provides key market trends and developments, growth drivers and future directions for each nation covered. Further, the research covers the nanotechnology patent analyses, including the number of patent publications and global top assignees of nanotechnology patent literature. It also covers the global RnD funding for the nanotechnology industry, including break-ups for corporate, public and venture capital funding along with their forecasts. The report even covers country-level analysis of R&D funding to provide in-depth understanding about investment related to nanotechnology.

Companies discussed include: Altair Nanotechnologies Inc., Nanophase Technologies Corporation, Nanosys, Inc., Unidym, Inc., Ablynx, NanoScale Corporation, Zyvex Corporation, Acusphere, Inc., SouthWest NanoTechnologies, Inc., and Applied Nanotech Holdings, Inc.

Report Details:

Title: Nanotechnology Market Outlook 2017

Published: May, 2013

Pages:210

Price: US$ 1,500.00

Read more:
World Nanotechnology Market Potential Explored by RNCOS in New Topical Study Now Available at MarketPublishers.com

Read the Rest...

Nanotechnology Market Outlook 2017

§ May 25th, 2013 § Filed under Nano Medicine Comments Off on Nanotechnology Market Outlook 2017

NEW YORK, May 15, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Nanotechnology Market Outlook 2017

http://www.reportlinker.com/p01182994/Nanotechnology-Market-Outlook-2017.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Nanotechnology

Nanotechnology has been the greatest impetus to technological and industrial development in the 21st century and has been recognized as the resource for the next industrial revolution. The evolving technology has already influenced a large number of industrial segments, and the economic activity generated from it has been high in magnitude and wide in scope. The nanotechnology-based products, which have had a huge impact on almost each industrial sector, are now entering the consumer market in a big way.

In their latest research study, "Nanotechnology Market Outlook 2017", RNCOS' analysts have identified that the global nanotechnology industry has been growing at a rapid pace with rising applications in sectors like electronic, enegy, healthcare sector etc. In addition, market trends like nanotechnology-based thin film solar cells with high effieciency; nanomaterials with higher strength; robust growth in nanofibres and nanomedicine market; etc., are booming growth in this industry. Considering the above factors, the global nanotechnology market is anticipated to grow at a CAGR of around 19% during 2013-2017.

In the report, the analysts have studied the nanotechnology market by application, by component and by region. On the application front, they have analyzed nanotechnology use in electronics, energy, cosmetics, medical and defence sector. In addition, they have covered the current nanotechnology market and forecast for each of the above mentioned segments till 2017. In terms of component, the nanotechnology market can be segregated into nanomaterials, nanotools and nanodevices. The report covers their present and future shares in the market.

Further, country level analysis discusses nanotechnology market in major countries like USA, Germany, France, the U.K., Russia, etc., the present key growth drivers, and future directions for each nation. In addition, it covers the nanotechnology patent analyses, including number of patent publications and global top assignees of nanotechnology patent literature.

Besides this, the report covers the global R&D funding for the nanotechnology industry, including break-ups for corporate, public and venture capital funding along with their forecasts. The report even covers country-level analysis of R&D funding to provide in-depth understanding about investment related to nanotechnology.

With a view to providing a balanced outlook of the global nanotechnology market to clients, the report also includes the profiles of key industry players like Altair, Nanophase Tech and Nanosys, among others. Overall, the objective of the study is to help clients understand the prospects of the industry, and make sound investment decisions in view of the same.1. Analyst View2. Research Methodology3. Nanotechnology - An Introduction4. Key Market Trends and Developments4.1 Nanofibers Market Witnessing Robust Growth4.2 Nanomedicine - Becoming the Hottest Growing Sector4.3 Nanotechnology - Thin-Film Solar Cells with Record Efficiency4.4 Rising Applications of Nanomaterials with Higher Strength5. Nanotechnology Market Overview6. Industry Performance: Current and Future Outlook6.1 By R&D Funding6.1.1 Government6.1.2 Corporate6.1.3 Venture Capital6.2 By Major Applications6.2.1 Electronics6.2.1.1 Nanocircuits6.2.1.2 Nanowires6.2.1.3 NanoSensors6.2.2 Energy6.2.2.1 Energy Source6.2.2.2 Energy Conversion6.2.2.3 Energy Storage6.2.2.4 Energy Distribution6.2.3 Cosmetics6.2.3.1 Skin Care6.2.3.2 Hair Care6.2.4 Biomedical6.2.4.1 Drug Delivery6.2.4.2 Therapeutics6.2.4.3 Medical Materials and Implants6.2.4.4 Analytical Tools and Instruments6.2.4.5 Diagnostics6.2.5 Defense6.2.5.1 Military Vehicles6.2.5.2 Military Clothes6.2.5.3 Aeronautics6.2.5.4 Satellites7. Country-Level Analysis7.1 US7.2 Brazil7.3 Germany7.4 France7.5 UK7.6 Ireland7.7 Russia7.8 Japan7.9 South Korea7.10 Taiwan7.11 China7.12 India7.13 Australia8. Patents Analysis9. Competitive Landscape9.1 Altair Nanotechnologies Inc.9.2 Nanophase Technologies Corporation9.3 Nanosys, Inc.9.4 Unidym, Inc.9.5 Ablynx9.6 NanoScale Corporation9.7 Zyvex Corporation9.8 Acusphere, Inc.9.9 SouthWest NanoTechnologies, Inc.9.10 Applied Nanotech Holdings, Inc.

List of Figures:

The rest is here:
Nanotechnology Market Outlook 2017

Read the Rest...

Dr. Simó Schwartz- CIBBIM Coordinator, Nanomedicine Area at VHIIR – Video

§ May 25th, 2013 § Filed under Nano Medicine Comments Off on Dr. Simó Schwartz- CIBBIM Coordinator, Nanomedicine Area at VHIIR – Video


Dr. Simó Schwartz- CIBBIM Coordinator, Nanomedicine Area at VHIIR

By: VHIRtv

Continue reading here:
Dr. Simó Schwartz- CIBBIM Coordinator, Nanomedicine Area at VHIIR - Video

Read the Rest...

Polymers in Nanomedicine – Video

§ May 25th, 2013 § Filed under Nano Medicine Comments Off on Polymers in Nanomedicine – Video


Polymers in Nanomedicine
A video made for the macromolecules module of my chemistry degree course. References: 1) Mohanty, A.K et al, Biopolymers and Biocomposites, CRC Press (2005) ...

By: Spaggotmower's channel

More:
Polymers in Nanomedicine - Video

Read the Rest...

anirbandeep bose NanoMedicine Cancer Drug Delivery – Video

§ May 25th, 2013 § Filed under Nano Medicine Comments Off on anirbandeep bose NanoMedicine Cancer Drug Delivery – Video


anirbandeep bose NanoMedicine Cancer Drug Delivery
anirbandeep bose.

By: Anirbandeep Bose

View post:
anirbandeep bose NanoMedicine Cancer Drug Delivery - Video

Read the Rest...

Doctors Health Press Reports on Study: Nanomedicine Three Times More Effective in Treating Eye Infections

§ May 25th, 2013 § Filed under Nano Medicine Comments Off on Doctors Health Press Reports on Study: Nanomedicine Three Times More Effective in Treating Eye Infections

Boston, MA (PRWEB) April 29, 2013

Doctors Health Press, a division of Lombardi Publishing Corporation and publisher of various natural health newsletters, books, and reports, including the popular online Doctors Health Press e-Bulletin, is reporting on a new study finding nanomedicine to be three times more effective than conventional medications in the treatment of eye infections.

As Doctors Health Press e-Bulletin (http://www.doctorshealthpress.com/general-health-2/health-news/this-could-be-the-new-frontier-in-eye-health) notes, many people dont have perfect eyesight due to injury, age-related wear and tear, and disease. For those who dont have good eyesight, they might find it difficult to read from afar, or may feel like everything is constantly blurry. For some people, this may be a temporary state, but for many unfortunate others, poor eyesight is a permanent fact of life.

As the article This Could Be the New Frontier in Eye Health reports, one of the main triggers for poor eyesight is the presence of a corneal infection. Many times, people find that, somehow, bacteria are able to invade the cornea after surgeryand thats when an infection can set in.

These infections can be serious, causing irritation, ruptures, and inflammation. If left untreated, blurry vision, and even blindness, can result. In addition, this type of infection is much more widespread these days, due to the increase in corneal surgeries for cataracts, glaucoma, and other conditions.

The Doctors Health Press e-Bulletin article states that researchers have discovered that they can use nanomedicine to improve the delivery and quantity of medicine that an infected eye receives.

Normally, conventional drops are put into the eye; with this type of drug delivery, scientists estimate a mere five percent of the medicine actually reaches the site of infection. Since the patients natural tendency is to blink and tear up whenever something touches their eyeball, an even greater amount of the medicine is washed away, making these conventional drugs very ineffective.

But according to the article, thats where nanomedicine comes in. Scientists have come up with a way to get drugs directly where they are needed in the right quantities. Soft contacts can be filled with nanoparticle drugs and delivered to a precise spot on the eye. Not only that, but the medicine can be released over a sustained period of time.

Doctors Health Press e-Bulletin reports that a research team recently tested the effects of nanomedicine on dogs with glaucoma. They delivered a drug called timolol through contact lenses. Because the nanomedicine was concentrated and potent, only one-third of a dose was needed to reduce ocular pressure when compared to conventional eye drops. The researchers also experimented by adding vitamin E to the nanomedicine, which had the effect of prolonging the release of the timolol.

As Doctors Health Press e-Bulletin concludes, this research has the potential to change the lives of people with vision problems.

Read the rest here:
Doctors Health Press Reports on Study: Nanomedicine Three Times More Effective in Treating Eye Infections

Read the Rest...

Big drugmakers think small with nanomedicine deals

§ May 25th, 2013 § Filed under Nano Medicine Comments Off on Big drugmakers think small with nanomedicine deals

By Ben Hirschler

LONDON (Reuters) - Is nanomedicine the next big thing? A growing number of top drug companies seem to think so.

The ability to encapsulate potent drugs in tiny particles measuring billionths of a meter in diameter is opening up new options for super-accurate drug delivery, increasing precision hits at the site of disease with, hopefully, fewer side effects.

Three deals struck this year by privately held Bind Therapeutics, together worth nearly $1 billion if experiments are successful, highlight a new interest in using such tiny carriers to deliver drug payloads to specific locations in the body.

U.S.-based Bind is one of several biotechnology firms that are luring large pharmaceutical makers with a range of smart drug nanotechnologies, notably against cancer.

And nanomedicine is also being put to work in diagnosis, with tiny particles used to improve imaging in scanners, as well as rapidly detecting some serious infections.

In future, researchers hope to combine both treatment and diagnostics in a new approach dubbed "theranostics" that would allow doctors to monitor patients via their medicines.

After much hype but limited clinical success, scientists in the nanotechnology field finally see a turning point.

"We have been hearing about the promise of nanomedicine for a long time, but it is now really starting to move," said Dan Peer, who runs a nanomedicine laboratory at Tel Aviv University.

"There is a new level of confidence in this approach among the big pharmaceutical companies ... We will see more and more products in clinical testing over the next few years and I think that is very exciting."

Read more:
Big drugmakers think small with nanomedicine deals

Read the Rest...

Nanomedicine Activity and Deployment Could Boost Nuvilex

§ May 25th, 2013 § Filed under Nano Medicine Comments Off on Nanomedicine Activity and Deployment Could Boost Nuvilex

BALTIMORE, MD--(Marketwired - May 23, 2013) - Goldman Small Cap Research, a stock market research firm focused on the small cap and microcap sectors, believes that a slew of recent activity which has occurred in the nanomedicine, or nanobiotechnology industry, bodes well for Nuvilex Inc. (OTCQB: NVLX). The Company is an international firm engaged in live-cell encapsulation technology to treat pancreatic cancer along with the development and study of the use of medical marijuana for the treatment of oncology patients.

According to a recent Reuters article, nanomedicine is defined as: "The ability to encapsulate potent drugs in tiny particles measuring billionths of a meter in diameter is opening up new options for super-accurate drug delivery, increasing precision hits at the site of disease with, hopefully, fewer side effects."

It sounds very much like the definition for Nuvilex's Cell-in-a-Box technology.

In the past two months alone, privately held nanobiotechnology leader Bind Therapeutics has closed 3 development deals with drug giants Pfizer, Amgen, and AstraZeneca.Significant upfront dollars have been paid and if all of the proposed drugs under development were to receive approval, it could be worth at least several hundred million dollars to Bind Therapeutics.

It is apparent that the methodology behind the delivery methods of both firms are remarkably similar, as is the primary targeted disease: cancer.In both cases, pro-drugs are encapsulated and targeted directly at the tumor with greater efficacy than traditional methods and with far less toxicity.

Clearly, a great deal of attention and value is beginning to occur for firms developing tiny, targeted delivery systems to treat major diseases like cancer.As Nuvilex edges closer to developing protocols for future trials, industry observers may begin to mention the Company in the same breath as the leading nanobiotechnology firms.

A copy of this article as well as other articles and Nuvilex reports can be accessed or downloaded in their entirety by visiting http://www.goldmanresearch.com.

About Goldman Small Cap Research: Led by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces small cap and micro cap stock research reports, daily stock market blogs, and popular investment newsletters.For more information, visit http://www.goldmanresearch.com.

A Goldman Small Cap Research report is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed.Please read the report's full disclosures and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other agency. To download our research, view our disclosures, or for more information, visit http://www.goldmanresearch.com.

About Nuvilex, Inc. (OTCQB: NVLX): Nuvilex, Inc. has been a provider of all-natural products for many years, has expanded its company to increase its natural product based footprint through medical marijuana studies and is becoming an international biotechnology provider of live, therapeutically valuable, encapsulated cells and services for treatments, research and medicine. The Company's offerings will ultimately include cancer, diabetes and other clinical treatments using the company's natural product knowledge, product base, cell and gene therapy expertise, and live-cell encapsulation technology in addition to other new products currently under development. For more information visit: http://www.nuvilex.com.

Read the original post:
Nanomedicine Activity and Deployment Could Boost Nuvilex

Read the Rest...

NANOMEDICINE AT TEL AVIV UNIVERSITY – Video

§ May 24th, 2013 § Filed under Nano Medicine Comments Off on NANOMEDICINE AT TEL AVIV UNIVERSITY – Video


NANOMEDICINE AT TEL AVIV UNIVERSITY

By: CFTAU

Here is the original post:
NANOMEDICINE AT TEL AVIV UNIVERSITY - Video

Read the Rest...

nanomedicine – Video

§ May 21st, 2013 § Filed under Nano Medicine Comments Off on nanomedicine – Video


nanomedicine
My First Project.

By: CWSxLNR

Here is the original post:
nanomedicine - Video

Read the Rest...

Scientists made fundamental discovery about how properties of embryonic stem cells controlled

§ May 12th, 2013 § Filed under Nano Medicine Comments Off on Scientists made fundamental discovery about how properties of embryonic stem cells controlled

Javascript is currently disabled in your web browser. For full site functionality, it is necessary to enable Javascript. In order to enable it, please see these instructions. May 02, 2013

The study, which focuses on the process by which these cells renew and increase in number, could help research to find new treatments.

Researchers have found that a protein, which switches on genes to allow embryonic stem cells to self-renew, works better when the natural occurring level of the protein is reduced.

It was previously thought that once levels of this protein called Oct 4 were reduced the numbers of new stem cells being produced would also fall.

The finding will inform stem cell research, which is looking to find treatments for conditions including Parkinson's, motor neurone, liver and heart disease.

During embryonic development, cells that have the capacity to become any cell type in the body called pluripotent stem cells can either renew themselves by multiplying in number or differentiate to become cells found in different parts of the body, for instance skin or liver.

This need for pluripotent cells to increase in number is important so that there is a sufficient supply of them to be differentiated into other cell types.

Scientists at the Medical Research Council Centre for Regenerative Medicine at the University of Edinburgh found that when there were lower levels of Oct 4, the protein bound much more tightly to key parts of DNA in cells.

The strong attraction of Oct 4 to these sections of DNA enabled the efficient switching on of key genes that caused pluripotent stem cells to renew.

The findings could help to improve the way in which stem cells are cultured in the laboratory, providing a better understanding of the processes needed for cells to divide and multiply or to generate different cell types.

Source:
http%3A//phys.org/news286711068.html

Read the Rest...

Marketing food supplements with health claims in the EU: key challenges in 2013 and beyond

§ May 5th, 2013 § Filed under Nano Medicine Comments Off on Marketing food supplements with health claims in the EU: key challenges in 2013 and beyond

By Elodie Lebastard and Stefanie Geiser, EAS Strategic Advice (Europe office), info@eas.eu, http://www.eas.eu

Companies are facing a range of regulatory challenges for the marketing of their food supplement products with health claims in the European Union (EU). These include having to adapt to various national differences on rules related to product composition, and EU-wide and/or national rules related to health claims and labelling.

While the EU Food Supplement Directive, which recently celebrated its 10-year anniversary. brought harmonised rules across the EU on the permitted use of specific vitamin and mineral chemical forms in food supplements, many other rules are still unharmonised and subject to divergent national rules across the 27 EU Member States. These include rules on vitamin/mineral maximum limits and on the permitted use of botanicals and other ingredients with a nutritional and/or physiological effect (bioactive substances).

In addition, 2013 has set a tough line for the labelling and advertising of food supplements in the EU. The transition period for the use of generic (Article 13.1) health claims not authorised by the European Commission ended in December 2012, and all health claims for health food products must now be in line with those authorised for use in the EU claims register.

The following is an overview of the key challenges companies are facing related to food supplements and health claims.

FOOD SUPPLEMENTS

Maximum levels for vitamins and minerals

The EU food supplement Directive 2002/46/EC foresees the setting of maximum/minimum amounts for vitamins and minerals in food supplements and requires the following criteria to be taken into consideration for their establishment:

  1. upper safe levels of vitamins and minerals established by scientific risk assessment based on generally accepted scientific data, taking into account, as appropriate, the varying degrees of sensitivity of different consumer groups;
  2. intake of vitamins and minerals from other dietary sources.

The Directive also states that reference intakes of vitamins and minerals for the population should be taken into account when setting maximum levels. However, since its adoption, harmonised maximum levels for vitamins and minerals have not yet been set. Work on this was initiated by the European Commission in 2006 but is still on hold, primarily due to political tensions among Member States on their divergent views.

In the absence of EU legislation, some Member States have set maximum levels for vitamins and minerals in their legislation. These include for example Belgium, Bulgaria, Cyprus, Denmark, France, Italy, Luxembourg, Malta and Slovenia. On the other hand, since 2002 a number of EU countries have removed existing national limits. These include Spain, the Czech Republic, Romania and Greece.

Botanicals and other bioactive substances

In the absence of harmonised EU legislation in this area, some Member States have set their own legislations on the use of plants and plant extracts and other bioactive substances in food supplements. Italy and Belgium, for example, have legal lists of botanicals that can be used in food supplements. Last year the Italian Ministry Decree on “the use of plant substances and preparations in food supplements” was officially adopted. The Decree foresees a positive list of plants with information on the permitted plant parts and, for certain plants, restrictions of use or warning statements. The 1997 Belgian Royal Decree on plants and plant preparations was also recently amended, and France too is developing a list of permitted botanicals in food supplements. In view of the increasing harmonised national initiatives on plant lists between Belgium, France and Italy, a joint project (so-called “BELFRIT” project) was initiated in 2013 between the Ministries of Health of these three countries. This could be an important start to expand and promote the botanical food supplement safety approach under food law taken by these three countries to a wider EU level. An international conference taking place in Rome on 18 April 2013 to present first results of the BELFRIT project will bring further insights into this.

With no EU-wide positive or negative list of botanicals and other bioactive substances for food supplements, the principle of mutual recognition can be the key to a successful pan-European marketing strategy. This derives from the EU principle of free movement of goods, meaning that each Member State is obliged to accept on its territory products lawfully manufactured and/or marketed in another Member State unless there is a safety concern. Companies having proof of products lawfully marketed in an EU country (e.g. via a free sales certificate obtained following product notification of the product in an EU Member State), should therefore try to make as much use of this principle as possible to expand their marketing to other EU countries.

HEALTH CLAIMS

Status of the authorised generic (Article 13.1) health claims list process

In 2012 the EU adopted a list of 222 generic health claims allowed to be made on foods (so-called first “Article 13.1 list”). These were included in the list of authorised health claims of the EU claims register. On the other hand, more than 1,600 claims rejected by the European Commission after the European Food Safety Authority (EFSA) assessment process have been included in the list of non-authorised claims. Authorised claims in the EU now predominantly relate to vitamins and minerals, with claims relating to other substances seeing only around 55 health relationships approved. A further set of six generic health claims, included in a regulation from the European Commission updating the Article 13.1 list of permitted claims, were adopted in February 2013. These relate to alpha-cyclodextrin, prunes, fructose, DHA and DHA/EPA.
On the other hand, claims for some other substances were once more put “on hold” to further clarify the conditions of use. These include:

  • five claims on caffeine, and EFSA has now been asked to give a safety assessment on caffeine before a decision can be taken;
  • one claim on carbohydrates and contribution to the maintenance normal brain function;
  • one claim relating to very low calorie diets and another claim on foods with reduced lactose content, which are pending the review of the legislation on foods for Particular Nutritional Uses (PARNUTS).

Most importantly, around 2,000 Article 13.1 claims for botanicals remain to be included on the revised “finalisation pending list” of the European Commission since the Commission still needs to decide which approach to take for botanical claims. These “on hold” claims may temporarily continue to be used on national markets in the EU as long as they meet the national claims provisions of the Member State authorities where marketed, and the European Commission has not yet taken a final decision on them.

Flexibility on enforcement in the Member States

With only few exceptions being “on hold” botanical and other claims, all other claims used in the EU must be in the authorised EU claims register list (which also provides the permitted claims wording), and it is not surprising that the result seems to be a very limited EU market picture made up of repetitive and identical claims.

Companies can, however, benefit from aspects of the regulation that are open to interpretation by Member States and/or the European Commission. Depending on national views, there can be a certain level of flexibility in their enforcement, for example:

  • Flexibility of health claims wording: Member States may be flexible in amending or broadening the wording/expressions of the authorised health claims in the EU claims register. In December 2012 the Member States agreed some “General principles on the flexibility of wording of authorised health claims”, and more specific detailed national claims guidelines have been developed by some, for example Belgium, Portugal and the Netherlands. The guidelines advise on aspects such as permitted or prohibited alternative wordings to the terms ‘contributes to’, ‘normal’ and ‘contains x’, and explain how permitted alternative terms as included in the EFSA claims opinions may be used.
  • Making use of general non-specific health benefit claims: Companies can use product names expressing simplified health effects and other easy, attractive statements (which by definition of Article 10(3) of the claims regulation “make reference to general, non-specific benefits of a food for overall good health or health-related well-being”) as long as these are accompanied by an authorised health claim. In January this year, the European Commission published guidelines clarifying that the authorised health claim accompanying the general, non-specific health benefit statement should be made ‘next to’ or ‘following’ the statement and should relate to the general reference.

Making use of the above rules in combination with the use of EU authorised health claims, can therefore be a potential avenue to cope with the new claims climate. Experience from acceptable market practice and learnings from national challenges will then show the way forward for 2013 and beyond.


EAS is attending the Vitafoods trade show in Geneva on 14-16 May 2013 where it will provide companies the opportunity to book free regulatory advisory sessions related to the marketing of food supplements and health claims at its stand. For further information: Please visit the EAS stand no. 11021 to book your session.

EAS is also organising a workshop in Brussels on 30 May 2013, which will give practical guidance to companies on how to avoid the pitfalls of food supplement and health claims rules. For further information visit http://www.eas.eu

Source:
http://www.nutraceuticalsnow.com/articles/2013/04/29/marketing-food-supplements-with-health-claims-in-the-eu-key-challenges-in-2013-and-beyond/

Read the Rest...

Foreword to the Spring 2013 Issue

§ May 5th, 2013 § Filed under Nano Medicine Comments Off on Foreword to the Spring 2013 Issue

Opportunities match challenges within the nutraceutical industry

By Chris Lee, Portfolio Director, Vitafoods Europe May 14-16, Palexpo, Geneva

Only the opportunities outnumber the challenges for anyone currently in the nutraceutical, functional food and drink and dietary supplement industries.

There’s little doubt that the introduction of the EFSA Article 13 health claims regulation, which came into effect at the end of 2012, is having a significant impact on the industry. The ruling, which has sparked debate throughout the industry, means that all 27 EU member states must now comply with the general health claim regulation to avoid prosecution for misleading marketing.

Ostensibly, this poses nothing but challenges for the industry. A raft of claims have become illegal and the scientific evidence required to justify claims has become greater than some firms are accustomed to, which could mean a reallocation of resources will be required to avoid extinction.

To focus solely on these challenges, however, means seeing only half of the picture. Firstly, it needs to be acknowledged that regulation is necessary – the industry’s credibility depends on preventing products carrying unsubstantiated or misleading claims. Furthermore, this raising of the barrier presents firms with the opportunity to promote the extensive research that substantiates their claims.

Of course, there are some in the industry who believe the process was flawed, providing insufficient guidance on the scientific studies that would be rejected. Others believe the low number of accepted claims will prompt cheap innovations to flood the market or that vague wording allows for the misinterpretation of claims.

The level of debate around this and the business benefits of exploring the opportunities and challenges posed by the new rulings prompted us to make regulation a major focus at Vitafoods Europe 2013, which for the first time ever includes a presentation by EFSA, followed by a live Q&A.

Professor Ambroise Martin, Chair, NDA Panel, EFSA Health Claims, is opening the conference programme with a presentation that outlines the need to look beyond the biased perception of Article 13. Furthermore, EAS Strategic Advice are hosting one-to- one consultations with visitors on the correct use of claims now that the regulation is in place.

While the introduction of regulation limits the number of approved claims to 222, it doesn’t prevent innovations being brought to market or companies obtaining health claims for new science-based products. It might be the case that new regulation directs product innovation, prompting companies to focus on claims already recognised by EFSA, but it certainly isn’t stopping innovation altogether.

Furthermore, alternative or less established ingredients are beginning to show their potential. Chia, for instance, surpasses flax (linseed) on several fronts, including fibre and alpha-linolenic acid (ALA) omega-3. It also has a more neutral flavour than flax and is more shelf-stable. Forward-thinking companies will begin to assess whether ingredients such as chia will overcome supply and cost issues to become the next star ingredient.

Similarly, omega-3 supplements have long been successful, but recently there has been excited talk about the prospects of high- end omega-3, which have been underlined by BASF and DSM’s increased investment in the sector.

Exciting trends and developments such as these are explored during the functional foods and consumer trends session at the Vitafoods Europe Conference, which is encompassing omega-3, probiotics and future opportunities, looking ahead to the trillion- dollar health and wellness industry of 2017.

Innovation is also set to be very much in evidence on the show floor, where products will be showcased by the industry’s major players, including BASF, Croda, DSM, Lonza and Naturex. Likewise the brand new Nutra Insights Hub features presentations from research bodies and industry associations, including GOED, Euromonitor, EAS Strategic Advice, European Nutraceutical Association, Innova Market Insights, Mintel and the International Probiotics Association. Additionally, visitors will be able to hear about exhibitors’ product launches at the Seminar Theatre, located on the show floor.

This year’s Vitafoods Europe has been expressly tailored to meet the needs of companies seeking to manage the challenges and seize the opportunities in the nutraceuticals industry – we’re looking forward to what we believe will truly be the must-attend industry event for 2013.

Register in advance to attend Vitafoods Europe and Finished Products Europe and save €100. http://www.vitafoods.eu.com/register or http://www.finishedproductseurope.com/register

For further details about Vitafoods Europe and Finished Products Europe, visit http://www.vitafoods.eu.com or http://www.finishedproductseurope.com. To hear about the latest show news or take part in the industry debate, join our Linkedin groups http://www.vitafoods.eu.com/linkedin or http://www.finishedproductseurope.com/linkedin or follow us on twitter @VitafoodsEurope or @fpeurope.

Source:
http://www.nutraceuticalsnow.com/articles/2013/04/29/foreword-to-the-spring-2013-issue/

Read the Rest...

Older, wiser, healthier

§ May 5th, 2013 § Filed under Nano Medicine Comments Off on Older, wiser, healthier

Maintaining the health of an ageing population is increasingly high on the agenda. Over the next 30 years, the number of over-65s in the world is expected to reach 1.3 billion and Europe is ageing the fastest. By 2040, it is estimated that over a quarter of Europeans will be at least 65. This demographic shift and its potential implications are leading to more focus on preventative strategies and lifestyle initiatives targeting seniors. Healthy diet lies at the heart of these strategies and the supplements and functional food and beverage markets will have a crucial role to play.

A changing world

Government bodies and health authorities across the world are raising awareness of the changing population. The World Health Organisation (WHO) made ageing its focus on its annual World Health Day in 2012 with the slogan ‘Good health adds life to years’. Campaign activities and materials focused on how good health throughout life can help older men and women lead full and productive lives and be a resource for their families and communities. A key recommended action point was the promotion of ‘healthy behaviours’ including eating a balanced diet.

The ageing European populace is also of central concern to Europe 2020, a strategy for European policy for the next decade. Its Innovation Partnership on Active and Healthy Ageing aims to address the issue and its main goal is to add two years to the average healthy European lifespan by 2020 through a variety of actions, including promoting and facilitating innovations in products, processes and services that will improve life for seniors. By reducing the time to market for innovative solutions for healthy ageing, it is hoped that many benefits will be produced for older people and their caregivers.

As the world wakes up to a changing population, functional food and beverage manufacturers must adapt to meet the needs of the burgeoning senior market. According to a recent international consumer survey, over a quarter of consumers aged 50-plus actively buy food and beverage products that improve health, in particular, heart health, digestive health and immune health.

There is significant scope for continued innovation as the number of older consumers increases and understanding the nutritional needs of this group will help manufacturers tailor their product formulations.

This article is available in full in the Spring 2013 issue of Nutraceuticals Now

Source:
http://www.nutraceuticalsnow.com/articles/2013/04/29/%EF%BF%BColder-wiser-healthier/

Read the Rest...

« Older Entries Newer Entries »



Page 30«..1020..29303132..4050..»